Navigation Links
New tool aims to improve measurement of primary care depression outcomes
Date:5/25/2011

ANN ARBOR, Mich. Primary care doctors have long been on the front lines of depression treatment. Depression is listed as a diagnosis for 1 in 10 office visits and primary care doctors prescribe more than half of all antidepressants.

Now doctors at the University of Michigan Health System have developed a new tool that may help family physicians better evaluate the extent to which a patient's depression has improved.

The issue, the researchers explain, is that the official definition of when a patient's symptoms are in remission doesn't always match up with what doctors see in a real-world practice, especially for patients with mild to moderate symptoms. The study will be published in the upcoming issue of General Hospital Psychiatry.

"Rather than simply going down a list and checking off a patient's lack of individual symptoms, we believe there are also positive signs that are important a patient's feeling that they are returning to 'normal,' their sense of well-being, their satisfaction with life and their ability to cope with life's ups and downs," says lead author Donald E. Nease Jr., M.D., who was an associate professor of family medicine at the U-M Medical School and member of the U-M Depression Center at the time of the research.

Nease and his colleagues developed a series of five questions such as, "Over the last two weeks, did you feel in control of your emotions?" that they hope will help doctors better understand a patient's inner landscape.

The remission criteria spelled out in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) doesn't necessarily correspond to a patient's own sense of recovery, Nease explains.

For example, a patient could meet all the criteria for full remission, but still not feel that he had recovered. The U-M questionnaire, which is called Remission Evaluation and Mood Inventory Tool, or REMIT, is intended to add the patient's subjective sense of recovery into the equation.

Rather than a replacement for current tools and measurements, REMIT is intended to compliment them, say Nease, who is currently an adjunct professor at U-M.

The researchers used the REMIT tool alongside the current "gold standard" for monitoring people with depression, the Patient Health Questionnaire (PHQ), Nease explains.

The data showed that by adding in the REMIT questions, about one-third of patients with mild depression were not in remission, as their PHQ score would indicate. Additionally, about one-third of moderately depressed patients were doing better than their PHQ scores alone would denote.

"Using just the PHQ score across our study population, we saw about 60 percent accuracy in reflecting a patient's remission compared to the patient's sense of his or her own recovery," Nease says. "If you add in the REMIT questions, we get above 70 percent. This can give doctors new insights when making treatment choices, such as changing a patient's medication or dosage."

The current research looked at a single snapshot in time for nearly 1,000 patients. The next step will be to track patients' scores over time.

Unlike other tools that require a company's permission to use, the REMIT tool is available to any doctor who wants to use it, Nease says.


'/>"/>

Contact: Ian Demsky
idemsky@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Brisk walking could improve prostate cancer outcomes
2. New study aims to improve long-term treatment for patients with bipolar disorder
3. Medicare improved Canadian doctors salaries: Queens University study
4. Patient navigators appear to improve colorectal cancer screening rate in ethnically diverse patients
5. Tort reform reduces lawsuit risk; establishes framework for quality improvements
6. Telemonitoring can improve overall survival of HF patients
7. New tool to measure outcomes could help improve arm surgery for devastating nerve injury
8. Strobe eyewear training may improve visual abilities
9. Curcumin compound improves effectiveness of head and neck cancer treatment, U-M study finds
10. Study Finds Ovarian Screening Tests Dont Improve Survival
11. Experts explore digital technologies potential to improve health care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... , ... According to research by the National Association of ... be certified or obtain continuing education. To increase patient awareness of the lack ... campaign to inform dentists and patients about the possible lack of skills and ...
(Date:2/7/2016)... Texas (PRWEB) , ... February 07, 2016 , ... ... new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and information ... MyDecision™ combines three elements to cut the cost of providing employee healthcare benefits ...
(Date:2/6/2016)... San Rafael, CA (PRWEB) , ... February 06, 2016 , ... ... 2016 Youth Ultimate Coaching Conference (YUCC) . This event brings together top non-profit leaders, ... is “Gender Equity and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... disorder treatment helps to reduce the frequency and level of relapse. ... Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the recovery ...
(Date:2/5/2016)... Ontario (PRWEB) , ... February 05, 2016 , ... ... announced the availability of the company's lighter, sleeker next generation LYNX VR Indoor ... plant. , Improvements in design and manufacturing not only reduce the weight ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016 Vestagen Technical Textiles, Inc., a medical ... healthcare and other demanding applications, today announced it has ... replaces Dale Pfost , PhD, who was serving ... also joining Vestagen,s Board of Directors. ® ... barrier technologies that combines fluid repellent, antimicrobial and breathability ...
(Date:2/8/2016)... Ill. , Feb. 8, 2016  Astellas Pharma Inc. ... announced the promotion of James Robinson as president, ... company,s operations in North and South America ... Astellas Pharma US, representing the commercial organization in ... in 2013. Masao Yoshida , who is ...
(Date:2/8/2016)... , Feb. 8, 2016  CTI BioPharma Corp. ... Company received written communication from the U.S. Food and ... FDA has placed a partial clinical hold on the ... Drug ("IND") application for pacritinib. This clinical hold impacts ... the IND and will also affect planned clinical trials. ...
Breaking Medicine Technology: